Clinical Trial Update: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating HepaStem for acute-on-chronic liver failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• On Chronic Liver Failure

Drugs mentioned

• HepaStem

Snippet

Sponsor: Cellaion SA | Conditions: Acute on Chronic Liver Failure | Phase 2 | Status: TERMINATED